# Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

> **NCT04047706** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 18 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** IDO1 Inhibitor BMS-986205 25mg
- **DRUG:** Nivolumab
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide
- **DRUG:** IDO1 Inhibitor BMS-986205 50 mg
- **DRUG:** IDO1 Inhibitor BMS-986205 100 mg

## Key facts

- **NCT ID:** NCT04047706
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-13
- **Primary completion:** 2027-02-15
- **Final completion:** 2027-06-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047706, "Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04047706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*